Featured

WHO SEARO Publishes Desk Review of Haemoglobinopathies in the South-East Asia Region
News

WHO SEARO Publishes Desk Review of Haemoglobinopathies in the South-East Asia Region

In an effort to understand the prevalence of thalassaemic syndromes and the existent blood supply system available within each country of the South-East Asia Region, the WHO Regional Office for…
World Patient Safety Day 2021: Act Now For Safe And Respectful Childbirth
Events

World Patient Safety Day 2021: Act Now For Safe And Respectful Childbirth

With the world still battling with the COVID-19 pandemic and the inequities that surfaced as a result, the most vulnerable and marginalized populations are being disproportionately affected due to both…
TIF Takes Active Part In The 71st Session of the WHO Regional Committee for Europe
News

TIF Takes Active Part In The 71st Session of the WHO Regional Committee for Europe

TIF has participated in the 71st session of the WHO Regional Committee for Europe between 13–15 September 2021, which gathered six hundred high-level delegates, including over 30 Health Ministers from…
EdiGene Announces First Patient Enrolment In Phase I Clinical Trial Of Gene-editing Therapy ET-01 For Patients With β-Thalassaemia
News

EdiGene Announces First Patient Enrolment In Phase I Clinical Trial Of Gene-editing Therapy ET-01 For Patients With β-Thalassaemia

The Chinese biotechnology company EdiGene announced yesterday that the first patient was enrolled in the multicentre, Phase I clinical study of its investigational gene editing hematopoietic stem cell therapy ET-01…
TIF Position Statement: Demanding Access To Existing And Upcoming Gene Therapies For β-Thalassaemia
Clinical News

TIF Position Statement: Demanding Access To Existing And Upcoming Gene Therapies For β-Thalassaemia

The Thalassaemia International Federation (TIF) is expressing its grave disappointment over the recent announcement of Bluebird Bio regarding the “wind-down” of its operations in Europe and the exclusive disposal of…
Mitapivat Granted Priority Review By The FDA For Pyruvate Kinase (PK) Deficiency
Clinical News

Mitapivat Granted Priority Review By The FDA For Pyruvate Kinase (PK) Deficiency

The U.S. Food and Drug Administration (FDA) has accepted Agios’ New Drug Application (NDA) for Mitapivat for the treatment of adults with pyruvate kinase (PK) deficiency. The NDA was granted…
TIF Presents The Federation’s Annual Report For 2020
News

TIF Presents The Federation’s Annual Report For 2020

“Our commitment to unite the patient voice and to advocate at the highest possible levels for equal access to all treatment options remains our number one priority.“ TIF President –…
CDC, FDA Authorize Third Dose Of COVID-19 Vaccines For The Immunocompromised In The US
Clinical News

CDC, FDA Authorize Third Dose Of COVID-19 Vaccines For The Immunocompromised In The US

The U.S. Food and Drug Administration (FDA) and the U.S. Centers for Disease Control and Prevention (CDC)  have both recommended on August 16 that certain immunocompromised people receive a third…
TIF e-Academy: Reimagining Thalassaemia and Sickle Cell Disease Education
TIF News

TIF e-Academy: Reimagining Thalassaemia and Sickle Cell Disease Education

Read. Learn. Empower. The Thalassaemia International Federation´s internationally acclaimed Educational Programme is a fundamental component of TIF´s work and is specifically designed for and addressed to the ever-growing learning needs…
Back to top button